Shares of ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) hit a new 52-week low during trading on Friday . The company traded as low as $2.96 and last traded at $3.02, with a volume of 565652 shares traded. The stock had previously closed at $3.04.
IBRX has been the subject of a number of research reports. Piper Sandler reduced their price target on shares of ImmunityBio from $6.00 to $4.75 and set a "neutral" rating for the company in a research report on Monday, August 19th. D. Boral Capital reaffirmed a "buy" rating and issued a $30.00 target price on shares of ImmunityBio in a report on Thursday, November 21st. Finally, EF Hutton Acquisition Co. I raised shares of ImmunityBio to a "strong-buy" rating in a report on Wednesday, October 23rd.
Read Our Latest Analysis on IBRX
The firm's 50-day moving average price is $4.57 and its 200 day moving average price is $4.89.
A number of large investors have recently bought and sold shares of the stock. Victory Capital Management Inc. increased its position in shares of ImmunityBio by 16.0% in the 2nd quarter. Victory Capital Management Inc. now owns 19,953 shares of the company's stock worth $126,000 after purchasing an additional 2,746 shares during the last quarter. Wealth Effects LLC grew its position in shares of ImmunityBio by 3.4% during the 3rd quarter. Wealth Effects LLC now owns 90,500 shares of the company's stock valued at $337,000 after buying an additional 3,000 shares during the last quarter. Exchange Traded Concepts LLC grew its position in shares of ImmunityBio by 8.4% during the 3rd quarter. Exchange Traded Concepts LLC now owns 47,984 shares of the company's stock valued at $178,000 after buying an additional 3,722 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of ImmunityBio by 22.0% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company's stock valued at $99,000 after buying an additional 4,545 shares during the last quarter. Finally, Courier Capital LLC grew its position in shares of ImmunityBio by 50.0% during the 3rd quarter. Courier Capital LLC now owns 30,000 shares of the company's stock valued at $112,000 after buying an additional 10,000 shares during the last quarter. Hedge funds and other institutional investors own 8.58% of the company's stock.
ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider ImmunityBio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmunityBio wasn't on the list.
While ImmunityBio currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.